Please login to the form below

Not currently logged in


This page shows the latest arthritis news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos have announced that their oral JAK inhibitor filgotinib has hit its goal in phase III trials in patients with rheumatoid arthritis who have failed on other treatments. ... The FINCH 2 trial of filgotinib in adults with

Latest news

More from news
Approximately 99 fully matching, plus 636 partially matching documents found.

Latest Intelligence

  • Insights from Cannes Lions Health Festival 2018 Insights from Cannes Lions Health Festival 2018

    When we think of arthritis we think of the old and frail. ... But Systemic Juvenile Idiopathic Arthritis (sJIA) actually affects a significant number of children.

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • The good, the bad and the ugly The good, the bad and the ugly

    Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic

  • The tipping point The tipping point

    In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.

  • Mobile health and patient outcomes Mobile health and patient outcomes

    In a recent study in rheumatoid arthritis, patients saw pain as the key measure of treatment success, confounding the objective ‘clinical evidence’of improvement.

More from intelligence
Approximately 0 fully matching, plus 42 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Havas Lynx Scoops Healthcare Agency of the Year at Cannes Lions 2018

    The first was in the Product Innovation category for Ouchie, a campaign designed to raise awareness and support children with JIA (Junior Idiopathic Arthritis).

  • Hanson Zandi

    We have extensive experience in the following therapeutic areas:. Analgesia. Arthritis.

  • Living with RA Report

    Living with RA Report. Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.

  • Infographic: RA market snapshot

    Infographic: RA market snapshot. An overview of the RA biologic patient. Our RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses are based on 139, 984

  • Research Partnership publishes 2016 Living with RA reports

    Research Partnership publishes 2016 Living with RA reports. Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016. ... Living with RA is a quantitative study conducted online amongst 500 patients

More from PMHub
Approximately 10 fully matching, plus 34 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...